翻訳と辞書 |
Amylin Pharmaceuticals Inc. : ウィキペディア英語版 | Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin,〔(Lipodystrophy Orphan Drug Program. Amylin Pharmaceuticals. )〕 as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion. In December 2013, Amylin was acquired by AstraZeneca. ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Amylin Pharmaceuticals」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|